VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.
VTX-806 is an AAV-based gene therapy for Cerebrotendinous xanthomatosis (CTX). It delivers a codon-optimized version of the CYP27A1 gene to the liver with strong proof-of-concept data in animals. VTX-806 has received Orphan Drug designations from both the FDA and the European Commission (EC) and proposed IND Regulatory strategy is supported by the FDA.
VTX-801, Vivet’s investigational gene therapy for Wilson’s Disease (WD), has received Orphan Drug and Fast Track designations from both the FDA and the EC.
The WD Gateway trial has stopped recruitment and is now focused exclusively on long-term follow-up of the already treated patients, with five years of monitoring planned.
Data from this trial will be published as further results become available.
Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.
By developing a unique pipeline of liver-directed AAV products and pioneering new technologies, we strive to unlock life-changing treatments for those in need. Recognizing that neutralizing antibodies prevent 20–50% of people from accessing gene therapy, we are committed to creating innovative solutions giving chance to more patients for effective therapies and even possible cures. Our mission is to expand access and make a difference in the lives of patients who previously had limited or no treatment options.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
By developing a unique pipeline of liver-directed AAV products and pioneering new technologies, we strive to unlock life-changing treatments for those in need. Recognizing that neutralizing antibodies prevent 20–50% of people from accessing gene therapy, we are committed to creating innovative solutions giving chance to more patients for effective therapies and even possible cures. Our mission is to expand access and make a difference in the lives of patients who previously had limited or no treatment options.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Vivet Therapeutics is proud to announce that Lexeo Therapeutics has entered into an option agreement to secure an exclusive license to VTX-PID, our proprietary IgG-degrading
A single-dose AAV gene therapy designed to restore the bile transporter missing in progressive familial intrahepatic cholestasis type 2; and what a new preclinical study
VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human
Vivet Therapeutics is pleased to announce the presentation of two scientific posters at the 33rd Annual Congress of the European Society of Gene and Cell
Vivet Therapeutics is pleased to announce that our CEO, Jean-Philippe Combal, will be attending the Jefferies Global Healthcare Conference in London from November 18th to
Join our CEO, @Jean-Philippe Combal in the Big Apple for @Chardan’s 9th Annual Genetic Medicines Conference! The premier event will bring together groundbreaking thought leaders